Naveed Iqbal Siddiqi
Director/Board Member en Amolyt Pharma SAS .
Perfil
Naveed Iqbal Siddiqi is currently serving as a Non Executive Director at F2G Ltd., a Director at Sanifit Therapeutics SA, a Director at Amolyt Pharma SAS, a Director at ReViral Ltd., a Director at Alentis Therapeutics AG, and a Senior Partner at Novo Ventures 1 A.
In the past, he held positions as a Director at Paratek Pharmaceuticals, Inc., Avalyn Pharma, Inc., and VectivBio AG.
From 2010 to 2013, he was a Partner at Phase4 Partners Ltd., and from 2013 to 2018, he served as a Partner at Andera Partners SCA.
He also served as a Member-Supervisory Board at VectivBio Holding AG and had a brief stint at Nomura International Plc in 2004.
Cargos activos de Naveed Iqbal Siddiqi
| Empresas | Cargo | Inicio |
|---|---|---|
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01/09/2019 |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Director/Board Member | - |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Director/Board Member | - |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | 01/06/2021 |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Director/Board Member | - |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | 13/04/2023 |
Antiguos cargos conocidos de Naveed Iqbal Siddiqi.
| Empresas | Cargo | Fin |
|---|---|---|
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Private Equity Investor | 31/12/2018 |
Phase4 Partners Ltd.
 Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Investment Committee Member | 01/06/2013 |
Paratek Pharmaceuticals, Inc. /Old/
 Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Director/Board Member | 01/09/2012 |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 12 |
|---|---|
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
Phase4 Partners Ltd.
Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Finance |
Avalyn Pharma, Inc.
 Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Health Technology |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Health Technology |
Amolyt Pharma SAS
Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Health Technology |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Naveed Iqbal Siddiqi
